Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Combretastatin A1 Diphosphate + Cytarabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Combretastatin A1 Diphosphate | OXi4503|OXi-4503|CA1P | Combretastatin A1 Diphosphate (OXi4503) is a vascular disrupting agent that causes microtubule instability, resulting in blood vessel collapse and decreased tumor growth (PMID: 20974154, PMID: 26751478, PMID: 32236943). | ||
Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02576301 | Phase Ib/II | Combretastatin A1 Diphosphate Combretastatin A1 Diphosphate + Cytarabine | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS | Unknown status | USA | 0 |